341 related articles for article (PubMed ID: 24604675)
1. Comparison of urine cytology and fluorescence in situ hybridization in upper urothelial tract samples.
Reynolds JP; Voss JS; Kipp BR; Karnes RJ; Nassar A; Clayton AC; Henry MR; Sebo TJ; Zhang J; Halling KC
Cancer Cytopathol; 2014 Jun; 122(6):459-67. PubMed ID: 24604675
[TBL] [Abstract][Full Text] [Related]
2. Fluorescence in situ hybridization (FISH) in the diagnosis of bladder and upper tract urothelial carcinoma: the largest single-institution experience to date.
Gomella LG; Mann MJ; Cleary RC; Hubosky SG; Bagley DH; Thumar AB; McCue PA; Lallas CD; Trabulsi EJ
Can J Urol; 2017 Feb; 24(1):8620-8626. PubMed ID: 28263126
[TBL] [Abstract][Full Text] [Related]
3. Fluorescence in situ hybridization for detecting upper urinary tract tumors--a preliminary report.
Akkad T; Brunner A; Pallwein L; Gozzi C; Bartsch G; Mikuz G; Steiner H; Verdorfer I
Urology; 2007 Oct; 70(4):753-7. PubMed ID: 17991550
[TBL] [Abstract][Full Text] [Related]
4. Utility of a modality combining FISH and cytology in upper tract urothelial carcinoma detection in voided urine samples of Chinese patients.
Xu C; Zeng Q; Hou J; Gao L; Zhang Z; Xu W; Yang B; Sun Y
Urology; 2011 Mar; 77(3):636-41. PubMed ID: 21256577
[TBL] [Abstract][Full Text] [Related]
5. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology.
Skacel M; Fahmy M; Brainard JA; Pettay JD; Biscotti CV; Liou LS; Procop GW; Jones JS; Ulchaker J; Zippe CD; Tubbs RR
J Urol; 2003 Jun; 169(6):2101-5. PubMed ID: 12771727
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of fluorescence in situ hybridization as an ancillary tool to urine cytology in diagnosing urothelial carcinoma.
Veeramachaneni R; Nordberg ML; Shi R; Herrera GA; Turbat-Herrera EA
Diagn Cytopathol; 2003 Jun; 28(6):301-7. PubMed ID: 12768634
[TBL] [Abstract][Full Text] [Related]
7. Fluorescence in situ hybridization performed on exfoliated urothelial cells in patients with transitional cell carcinoma of the bladder.
Degtyar P; Neulander E; Zirkin H; Yusim I; Douvdevani A; Mermershtain W; Kaneti J; Manor E
Urology; 2004 Feb; 63(2):398-401. PubMed ID: 14972510
[TBL] [Abstract][Full Text] [Related]
8. Fluorescence in situ hybridization in 1 mL of selective urine for the detection of upper tract urothelial carcinoma: a feasibility study.
Freund JE; Liem EIML; Savci-Heijink CD; de Reijke TM
Med Oncol; 2018 Nov; 36(1):10. PubMed ID: 30499061
[TBL] [Abstract][Full Text] [Related]
9. Combined application of cytology and molecular urine markers to improve the detection of urothelial carcinoma.
Todenhöfer T; Hennenlotter J; Esser M; Mohrhardt S; Tews V; Aufderklamm S; Gakis G; Kuehs U; Stenzl A; Schwentner C
Cancer Cytopathol; 2013 May; 121(5):252-60. PubMed ID: 23172833
[TBL] [Abstract][Full Text] [Related]
10. Voided urine fluorescence in situ hybridization testing for upper tract urothelial carcinoma surveillance.
Johannes JR; Nelson E; Bibbo M; Bagley DH
J Urol; 2010 Sep; 184(3):879-82. PubMed ID: 20643443
[TBL] [Abstract][Full Text] [Related]
11. Fluorescence in situ hybridization assay detects upper urinary tract transitional cell carcinoma in patients with asymptomatic hematuria and negative urine cytology.
Huang WT; Li LY; Pang J; Ruan XX; Sun QP; Yang WJ; Gao X
Neoplasma; 2012; 59(4):355-60. PubMed ID: 22489689
[TBL] [Abstract][Full Text] [Related]
12. Role of Tetrasomy for the Diagnosis of Urothelial Carcinoma Using UroVysion Fluorescent In Situ Hybridization.
Zhou AG; Liu Y; Cyr MS; Garver J; Woda BA; Cosar EF; Hutchinson LM
Arch Pathol Lab Med; 2016 Jun; 140(6):552-9. PubMed ID: 27232347
[TBL] [Abstract][Full Text] [Related]
13. Utility of fluorescence in situ hybridization as a non-invasive technique in the diagnosis of upper urinary tract urothelial carcinoma.
Marín-Aguilera M; Mengual L; Ribal MJ; Musquera M; Ars E; Villavicencio H; Algaba F; Alcaraz A
Eur Urol; 2007 Feb; 51(2):409-15; discussion 415. PubMed ID: 17010508
[TBL] [Abstract][Full Text] [Related]
14. UroVysion® multiprobe FISH in the triage of equivocal urinary cytology cases.
Bubendorf L; Piaton E
Ann Pathol; 2012 Dec; 32(6):e52-6, 438-43. PubMed ID: 23244486
[TBL] [Abstract][Full Text] [Related]
15. UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer.
Moonen PM; Merkx GF; Peelen P; Karthaus HF; Smeets DF; Witjes JA
Eur Urol; 2007 May; 51(5):1275-80; discussion 1280. PubMed ID: 17084511
[TBL] [Abstract][Full Text] [Related]
16. [Predictive value of fluorescence in situ hybridization in patients with bladder cancer].
Shan ZF; Zheng SB; Wu P; Tan WL; Zuo Y; Zhou HK; Qi H; Zhang P; Peng HM
Nan Fang Yi Ke Da Xue Xue Bao; 2010 Jul; 30(7):1597-9, 1603. PubMed ID: 20650776
[TBL] [Abstract][Full Text] [Related]
17. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice.
May M; Hakenberg OW; Gunia S; Pohling P; Helke C; Lübbe L; Nowack R; Siegsmund M; Hoschke B
Urology; 2007 Sep; 70(3):449-53. PubMed ID: 17688921
[TBL] [Abstract][Full Text] [Related]
18. Surveillance of patients with bladder carcinoma using fluorescent in-situ hybridization on bladder washings.
Bergman J; Reznichek RC; Rajfer J
BJU Int; 2008 Jan; 101(1):26-9. PubMed ID: 17850364
[TBL] [Abstract][Full Text] [Related]
19. Modified UroVysion scoring criteria increase the urothelial carcinoma detection rate in cases of equivocal urinary cytology.
Huysentruyt CJ; Baldewijns MM; Rüland AM; Tonk RJ; Vervoort PS; Smits KM; van de Beek C; Speel EJ
Histopathology; 2011 Jun; 58(7):1048-53. PubMed ID: 21707706
[TBL] [Abstract][Full Text] [Related]
20. Intermediate-risk urothelial carcinoma: an unresolved problem?
Pycha A; Lodde M; Comploj E; Negri G; Egarter-Vigl E; Vittadello F; Lusuardi L; Palermo S; Mian C
Urology; 2004 Mar; 63(3):472-5. PubMed ID: 15028440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
